Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 7, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Ruxolitinib.

Stefanie Ajayi1,2, Heiko Becker1,2, Heike Reinhardt1,2

  • 1Department of Hematology and Oncology, University of Freiburg Medical Center, Hugstetter Str. 55, 79106, Freiburg, Germany.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|August 3, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Nature medicine·2026
Same author

Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

Nature medicine·2026
Same author

Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases.

HemaSphere·2026
Same author

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

American journal of hematology·2026
Same author

First-in-human EphA2-targeting PET imaging with the bicyclic radiotracer [<sup>68</sup>Ga]Ga-BCY18469 in pancreatic cancer patients: biodistribution, dosimetry and initial findings.

European journal of nuclear medicine and molecular imaging·2026
Same author

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

Nature medicine·2026
Same journal

Future Challenges of Molecular Imaging in Oncology.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Clinical Applications of Theranostics.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Internal Radiation Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

The Role of Molecular Imaging in Ion Beam Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Molecular Imaging in Photon Radiotherapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Advancements in Intraoperative Imaging for Enhanced Surgical Precision.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
See all related articles

Ruxolitinib effectively treats myelofibrosis and polycythemia vera by inhibiting Janus kinase (JAK) 1 and JAK2, reducing spleen size and improving symptoms. Further research explores its use in graft-versus-host disease.

Area of Science:

  • Pharmacology and Therapeutics
  • Oncology
  • Hematology

Background:

  • Myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV), involve aberrant JAK-STAT pathway activation.
  • MF presents with bone marrow fibrosis, splenomegaly, and debilitating symptoms, while PV is marked by excessive red blood cell production and thrombotic risks.
  • Ruxolitinib is an oral inhibitor targeting Janus kinase (JAK) 1 and JAK2, key mediators in MPN pathogenesis.

Purpose of the Study:

  • To review the efficacy and safety of ruxolitinib in treating MPNs.
  • To discuss its approved indications and emerging applications, such as graft-versus-host disease (GvHD).
  • To highlight considerations for its clinical use, including potential toxicities and drug interactions.

Main Methods:

Keywords:
Graft-versus-host diseaseMyelofibrosisPolycythemia veraRuxolitinib

More Related Videos

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
12:36

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

9.9K

Related Experiment Videos

Last Updated: Feb 7, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K
Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
12:36

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

9.9K
  • Review of clinical trial data and regulatory approvals for ruxolitinib in MF and PV.
  • Analysis of ruxolitinib's mechanism of action targeting the JAK-STAT pathway.
  • Examination of safety profiles, including myelosuppression and viral reactivation, and pharmacokinetic considerations.

Main Results:

  • Ruxolitinib demonstrated significant reduction in spleen size and symptom burden in MF patients, with potential survival benefits.
  • In PV, ruxolitinib effectively controlled hematocrit levels and reduced splenomegaly.
  • Ruxolitinib is under investigation for GvHD post-allogeneic hematopoietic stem cell transplantation (HSCT).

Conclusions:

  • Ruxolitinib is an effective treatment for MF and PV, offering significant clinical benefits.
  • Careful monitoring for toxicities like myelosuppression and awareness of CYP3A4 interactions are crucial for safe administration.
  • Ongoing research into ruxolitinib and other JAK inhibitors holds promise for managing MPNs and inflammatory conditions.